Clinical Trial Update: Safety, Tolerability and Pharmacokinetics of QAK423A in Healthy Volunteers and Chronic Obstructive Pulmonary Disease (COPD) Patients [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety, tolerability and pharmacokinetics of QAK423A in healthy volunteers and patients with chronic obstructive pulmonary disease.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• QAK423A

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Obstructive Pulmonary Disease | Phase 1 | Status: COMPLETED